J&J launches second PhIII COVID-19 trial
Janssen will enrol participants in countries with high incidence of COVID-19, including the UK
Read More
Tag: phase III
EMA, FDA both accept filing of Novartis’ ofatumumab
In two head-to-head studies, ofatumumab demonstrated superiority over Aubagio in patients with relapsing forms of multiple sclerosis.
Read More
Late-stage success for experimental migraine drug
The results support the filing of a New Drug Application (NDA) for Axsome’s AXS-07 in the acute treatment of migraine.
Read More
Investigational atopic dermatitis drug hits late-stage endpoints
There is currently a “critical need” for additional treatment options for atopic dermatitis.
Read More
GSK launches PhIII programme for otilimab in RA
The Phase III clinical programme is the first in RA to include head-to-head comparisons of otilimab with current treatments across all pivotal studies
Read More
NICE recommendation for MSD’s Prevymis after re-evaluation
Prevymis is a member of a new class of drugs called non-nucleoside CMV inhibitors.
Read More
Novartis hits targets in late-stage QMF149 asthma trial
The once-daily, fixed-dose treatment demonstrated significant improvements in lung function and asthma control.
Read More
Pfizer announces positive dermatitis therapy phase III results
The company’s Janus kinase 1 has met all co-primary and secondary endpoints in a pivotal Phase III study.
Read More
Novo Nordisk’s Victoza found to cut blood sugar in children
The ELLIPSE trial is the first Phase III trial completed in over a decade in children and adolescents with type II diabetes.
Read More
Phase III results move Aimmune’s peanut allergy drug closer to EU market
Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance.
Read More
Santhera’s Syros succesful in DMD study
Santhera Pharmaceuticals has announced results from its Syros DMD study.
Read More
Rexulti falls short of goal in late-stage bipolar disorder studies
Lundbeck’s Rexulti has failed to achieve the primary endpoint of two Phase III bipolar disorder studies.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
